Status:
ACTIVE_NOT_RECRUITING
Gene Molecular Alterations as Disease Prognostic Markers in Patients With Non-small Cell Lung Cancer (NSCLC)
Lead Sponsor:
Hellenic Cooperative Oncology Group
Conditions:
NSCLC (Non-small Cell Lung Cancer)
Eligibility:
All Genders
18+ years
Brief Summary
GEMA-proN is an observational, multicenter, single cohort, retrospective clinical trial. The aim of the trial is to assess the prevalence, and prognostic value of genetic molecular alterations and inv...
Detailed Description
This a non- interventional, multicenter, retrospective one arm trial assessing patients with histologically confirmed diagnosis of non-small cell lung cancer (NSCLC). Patients received treatment in 18...
Eligibility Criteria
Inclusion
- Age 18 and above.
- Histologically confirmed non-small cell lung cancer (NSCLC).
- Adequate, and suitable tissue for the testing of somatic genetic alterations.
Exclusion
- \- Patients with personal medical history of malignancy, other than non-small cell lung cancer (NSCLC), with the exclusion of completely resected non-melanoma skin cancers, in situ carcinomas of the cervix uteri, in situ bladder carcinomas, in situ ductal breast carcinoma, and other cancers treated with curative intent with no evidence of disease recurrence for 5 years.
Key Trial Info
Start Date :
September 9 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 15 2025
Estimated Enrollment :
367 Patients enrolled
Trial Details
Trial ID
NCT06876402
Start Date
September 9 2013
End Date
May 15 2025
Last Update
May 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hellenic Cooperative Oncology Group (HeCOG)
Athens, Greece, 11526